Donanemab shows promise in slowing Alzheimer's disease progression.

Eli Lilly's experimental drug, donanemab, has succeeded in a Phase III study, slowing cognitive and functional decline by 35% over 18 months in a subset of patients with early Alzheimer's disease. The company plans to submit the drug to the FDA this quarter. Meanwhile, Pfizer has disclosed the discontinuation of six pipeline projects, and Boehringer Ingelheim is investing $313.4 million into a new chemical innovation plant at its headquarters in Germany.